openPR Logo
Press release

Sensorineural Hearing Loss Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics, Akouos

07-30-2025 09:34 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Sensorineural Hearing Loss Pipeline 2025: Comprehensive

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Sensorineural Hearing Loss pipeline constitutes 20+ key companies continuously working towards developing 21+ Sensorineural Hearing Loss treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Sensorineural Hearing Loss Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sensorineural Hearing Loss Market.

The Sensorineural Hearing Loss Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Sensorineural Hearing Loss Pipeline Report: https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Sensorineural Hearing Loss treatment therapies with a considerable amount of success over the years.
• Sensorineural Hearing Loss companies working in the treatment market are Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others, are developing therapies for the Sensorineural Hearing Loss treatment
• Emerging Sensorineural Hearing Loss therapies in the different phases of clinical trials are- ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others are expected to have a significant impact on the Sensorineural Hearing Loss market in the coming years.
• In February 2025, SPI-1005 was an investigational drug featuring ebselen, a novel seleno-organic compound. Ebselen functions by mimicking and stimulating glutathione peroxidase (GPx) activity, helping reduce neuroinflammation in both the central and peripheral nervous systems. GPx plays a vital role in protecting various tissues, including those in the inner ear, retina, brain's prefrontal cortex, lungs, and kidneys. Its activity often declines due to aging or environmental damage. Research in multiple animal models has linked reduced GPx activity to the development of sensorineural hearing loss.

Sensorineural Hearing Loss Overview
Sensorineural hearing loss (SNHL) occurs due to damage to inner ear structures or the auditory nerve. It accounts for over 90 percent of hearing impairment in adults. Typical causes of SNHL include prolonged exposure to loud noises, genetic predisposition, or the natural aging process.

Get a Free Sample PDF Report to know more about Sensorineural Hearing Loss Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Sensorineural Hearing Loss Drugs Under Different Phases of Clinical Development Include:
ACOU085: Acousia Therapeutics
• Cochlear Hair Cell Regeneration: Decibel Therapeutics
• HY01: Suzhou Pharmaceutical Technology Co.,Ltd
• AC102: AudioCure Pharma GmbH
• SENS-401: Sensorion

Sensorineural Hearing Loss Route of Administration
Sensorineural Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Sensorineural Hearing Loss Molecule Type
Sensorineural Hearing Loss Products have been categorized under various Molecule types, such as
• Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Sensorineural Hearing Loss Pipeline Therapeutics Assessment
• Sensorineural Hearing Loss Assessment by Product Type
• Sensorineural Hearing Loss By Stage and Product Type
• Sensorineural Hearing Loss Assessment by Route of Administration
• Sensorineural Hearing Loss By Stage and Route of Administration
• Sensorineural Hearing Loss Assessment by Molecule Type
• Sensorineural Hearing Loss by Stage and Molecule Type

DelveInsight's Sensorineural Hearing Loss Report covers around 21+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Sensorineural Hearing Loss product details are provided in the report. Download the Sensorineural Hearing Loss pipeline report to learn more about the emerging Sensorineural Hearing Loss therapies
https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Sensorineural Hearing Loss Therapeutics Market include:
Key companies developing therapies for Sensorineural Hearing Loss are - Sensorion, Fennec Pharmaceuticals, Sound Pharmaceuticals, Decibel Therapeutics, Akouos, and others.

Sensorineural Hearing Loss Pipeline Analysis:
The Sensorineural Hearing Loss pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sensorineural Hearing Loss with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sensorineural Hearing Loss Treatment.
• Sensorineural Hearing Loss key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sensorineural Hearing Loss Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sensorineural Hearing Loss market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Sensorineural Hearing Loss drugs and therapies
https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Sensorineural Hearing Loss Pipeline Market Drivers
• Rise in the Incidence of Sensorineural hearing loss, rising Awareness and Initiatives about Hearing loss are some of the important factors that are fueling the Sensorineural Hearing Loss Market.

Sensorineural Hearing Loss Pipeline Market Barriers
• However, high Cost of treatment, presence of Substitute Products and other factors are creating obstacles in the Sensorineural Hearing Loss Market growth.

Scope of Sensorineural Hearing Loss Pipeline Drug Insight
• Coverage: Global
• Key Sensorineural Hearing Loss Companies: Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others
• Key Sensorineural Hearing Loss Therapies: ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others
• Sensorineural Hearing Loss Therapeutic Assessment: Sensorineural Hearing Loss current marketed and Sensorineural Hearing Loss emerging therapies
• Sensorineural Hearing Loss Market Dynamics: Sensorineural Hearing Loss market drivers and Sensorineural Hearing Loss market barriers

Request for Sample PDF Report for Sensorineural Hearing Loss Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/sensorineural-hearing-loss-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Sensorineural Hearing Loss Report Introduction
2. Sensorineural Hearing Loss Executive Summary
3. Sensorineural Hearing Loss Overview
4. Sensorineural Hearing Loss- Analytical Perspective In-depth Commercial Assessment
5. Sensorineural Hearing Loss Pipeline Therapeutics
6. Sensorineural Hearing Loss Late Stage Products (Phase II/III)
7. Sensorineural Hearing Loss Mid Stage Products (Phase II)
8. Sensorineural Hearing Loss Early Stage Products (Phase I)
9. Sensorineural Hearing Loss Preclinical Stage Products
10. Sensorineural Hearing Loss Therapeutics Assessment
11. Sensorineural Hearing Loss Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Sensorineural Hearing Loss Key Companies
14. Sensorineural Hearing Loss Key Products
15. Sensorineural Hearing Loss Unmet Needs
16 . Sensorineural Hearing Loss Market Drivers and Barriers
17. Sensorineural Hearing Loss Future Perspectives and Conclusion
18. Sensorineural Hearing Loss Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Sensorineural Hearing Loss Market https://www.delveinsight.com/report-store/sensorineural-hearing-loss-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Sensorineural Hearing Loss Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Latest Reports:
• Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
• Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sensorineural Hearing Loss Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Sensorion, Fennec Pharma, Sound Pharma, Decibel Therapeutics, Akouos here

News-ID: 4127133 • Views:

More Releases from DelveInsight Business Research

Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Companies
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, DelveInsight Finds
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics. DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,

All 5 Releases


More Releases for Sensorineural

Sudden sensorineural hearing loss Market is expected to reach USD 1.56 billion b …
Sudden sensorineural hearing loss (SSNHL) is an unexplained, rapid loss of hearing-typically in one ear-occurring over a 72-hour period or less. It often affects otherwise healthy individuals and is considered a medical emergency. While the exact cause remains unknown in many cases, viral infections, vascular compromise, and autoimmune disorders are among the suspected triggers. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70760 This condition affects approximately 5-27 per 100,000 people
Sensorineural Hearing Loss Pipeline: 20+ Innovators Shaping the Future of Hearin …
The sensorineural hearing loss space is entering a transformative phase with groundbreaking innovations in gene therapy and regenerative medicine. Pioneering companies such as Sensorion, AudioCure Pharma, Audion Therapeutics, Reyon Pharmaceutical, and Decibel Therapeutics are developing therapies aimed at repairing damaged sensory cells and restoring hearing function. These novel approaches are targeting the underlying causes of hearing loss at a molecular level, offering hope for patients with sensorineural hearing loss and
Acute Sensorineural Hearing Loss Treatment Market to Garner Brimming Revenues by …
Global Acute Sensorineural Hearing Loss Treatment Market: Introduction Acute sensorineural hearing loss occurs when the inner ear, the cochlea in the inner ear, or the nerve pathways between the ear and the brain get damaged. Audiometry tests can check human hearing more thoroughly and precisely. During these tests, an audiologist tests the patient's hearing ability by using earphones. A series of different sounds and volume levels is sent to each ear
Acute Sensorineural Hearing Loss Treatment Market: Which application is anticipa …
The report attempts to offer high-quality and accurate analysis of the global Acute Sensorineural Hearing Loss Treatment Market, keeping in view market forecasts, competitive intelligence, and technological risks and advancements, and other important subjects. Its carefully crafted market intelligence allows market participants to understand the most significant developments in the global Acute Sensorineural Hearing Loss Treatment market that are impacting their business. Readers can become aware of crucial opportunities available
EU grants orphan drug status to Strekin’s STR001 for Sudden Sensorineural Hear …
European Medicine Agency (EMA) has granted orohan drug designation to Sterkin AG, a clinical stage biopharmaceutical company’s development candidate STR001 for the treatment of patients with Sudden Sensorineural Hearing Loss. FDA and EMA grants orphan drug designation to those products like drugs and therapies that treat rare diseases. The administration defines rare diseases as those affecting fewer than 200,000 people in United States. Orphan drug designation provides certain financial benefits such
Therapeutics Clinical Trials On Acute Sensorineural Hearing Loss: Global Review, …
Researchmoz added Most up-to-date research on "Therapeutics Clinical Trials On Acute Sensorineural Hearing Loss: Global Review, H1, 2017" to its huge collection of research reports. GlobalData's clinical trial report, Acute Sensorineural Hearing Loss Global Clinical Trials Review, H1, 2017" provides an overview of Acute Sensorineural Hearing Loss clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Sensorineural Hearing Loss. Report includes an overview of